Navigation Links
Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract

Therapure to provide specialized formulation and fill services

(PRWEB) December 11, 2009 -- Therapure Biopharma Inc. today announced the signing of an exclusive supply agreement with Akorn Inc. (NASDAQ: AKRX). This agreement will support Akorn’s new product development initiatives.

Under the terms of the partnership, Therapure Biopharma will provide product formulation, process development, and sterile fill/finish services to support the development of new hospital products by Akorn. Therapure Biopharma will provide these services in its Health Canada licensed facility in Mississauga, Ontario.

“We are proud that Akorn has chosen Therapure Biopharma as a strategic partner for the development of these new products,” said Thomas Wellner President and CEO of Therapure Biopharma Inc. “Therapure Biopharma has experience in meeting the needs of customers for specialized fill/finish services and we were able to respond quickly to Akorn’s particular requirements.”

“Akorn carries a broad catalogue of sterile specialty pharmaceutical products”, said Sean Brynjelsen, Akorn’s Vice President of New Business Development. “Therapure Biopharma was able to quickly respond to our need for specialty formulation and fill/finish services. The signing of this exclusive supply agreement reinforces Akorn’s commitment to expanding our portfolio through partnering.”

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit:

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.

For more information, please visit

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
3. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
6. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
9. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Post Your Comments:
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse and ... findings on the website. Click here to read the details now. ... were treated with chemotherapy followed by EPP surgery. Among the 106 patients who relapsed, ...
(Date:11/27/2015)... ... 27, 2015 , ... The print component of “Supporting Our ... Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 copies ... a vast social media strategy and across a network of top news sites ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... ... on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical ... of CAAHEP accredited colleges, as only one of twelve colleges and universities in the ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Therapeutic Drug Monitoring (TDM) Market: ... Intelligence, Emerging Opportunities"  report to their ... has announced the addition of the  ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology: